FDA
-
-
-
-
-
-
-
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
-
-
-
-
-
-
-
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) Rusfertide's Clinical Hold is Lifted Faster Than Expected - Piper Sandler
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)
-
-
-
-
-
-
-
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

